GCV Israel 2018
Skip Content

12 January 2018

Celgene provides Sanofi with $1.1bn Impact exit

Sanofi will exit cancer drug developer Impact Biomedicines in an acquistion by Celgene that consists of $1.1bn up front and potentially billions in milestone payments.

Author: Robert Lavine, News Editor

Pharmaceutical firm Celgene has agreed to acquire US-based cancer treatment developer Impact Biomedicines in a $1.1bn deal that will give an exit to fellow pharmaceutical company Sanofi.